National Blood Clot Alliance (NBCA) Designates Two AdventHealth Hospitals as Centers of Excellence for VTE Care
Recognition Highlights AdventHealth's Commitment to Exceptional Care in Blood Clot Prevention, Diagnosis, and Treatment
'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents.'— Dr. Arkadiy Kheyfits, AdventHealth Palm Coast and Palm Coast Parkway
PALM COAST, FL, UNITED STATES, May 15, 2025 / EINPresswire.com / -- The National Blood Clot Alliance (NBCA) is proud to announce the designation of AdventHealth Palm Coast and AdventHealth Palm Coast Parkway as NBCA Venous Thromboembolism (VTE) Centers of Excellence™. These hospitals are the first in the AdventHealth system and the first in Northeast Florida to earn this prestigious recognition for their commitment to delivering exceptional, patient-centered care in the prevention, diagnosis, and treatment of blood clots.
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a significant public health concern in the United States. According to the Centers for Disease Control and Prevention (CDC), up to 900,000 people in the U.S. are affected by VTE each year, and as many as 100,000 die as a result. Despite these alarming numbers, VTE remains underdiagnosed and undertreated—highlighting the importance of comprehensive, multidisciplinary approaches to care.
'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents' said Dr. Arkadiy Kheyfits, Interventional Radiologist at AdventHealth Palm Coast and Palm Coast Parkway.' I believe AdventHealth Palm Coast and Palm Coast Parkway are leaders in this space, and I am excited to continue improving our care and prevention pathways.'
As NBCA VTE Centers of Excellence™, both AdventHealth Palm Coast campuses join a growing network of leading institutions recognized for advancing VTE care through clinical excellence, innovation, and a commitment to education and prevention. This expanding network includes distinguished centers such as Corewell Health West Butterworth Hospital in Grand Rapids, MI, and Ascension Sacred Heart Hospital in Pensacola, FL.
'NBCA VTE Centers of Excellence™ are setting a new standard in how we approach VTE—from acute management to long-term prevention,' said Erin VanDyke, PA-C, Vice President of the NBCA COE Program. 'The teams at AdventHealth Palm Coast and Palm Coast Parkway exemplify the mission of this program through their multidisciplinary collaboration, dedication to best practices, and focus on patient outcomes. We are proud to welcome them as the first designated Centers of Excellence in both the AdventHealth system and Northeast Florida.'
The NBCA COE program aims to improve outcomes and save lives by partnering with institutions that embrace innovative, evidence-based, and patient-focused strategies to prevent and treat VTE.
To learn more about the NBCA VTE Centers of Excellence™ program, visit stoptheclot.org.
About the National Blood Clot Alliance (NBCA)
Established in 2003, the National Blood Clot Alliance (NBCA) is the nation's leading nonprofit, patient advocacy organization dedicated to advancing the prevention, early diagnosis, and treatment of life-threatening blood clots. Through a strategic focus on education, advocacy, and research, NBCA empowers patients and families, supports healthcare professionals, and drives national efforts to improve awareness, detection, and outcomes related to VTE. NBCA leads initiatives that strengthen the standard of care and foster innovation in VTE prevention and treatment across the United States.
About AdventHealth
AdventHealth is a connected network of care that helps people feel whole – body, mind and spirit. More than 100,000 team members across a national footprint provide whole-person care to nearly nine million people annually through more than 2,000 care sites that include hospitals, physician practices, ambulatory surgery centers, outpatient clinics, home health agencies, hospice centers, the AdventHealth app and more. Our wholistic approach to improving the health and prosperity of our communities is inspired by our mission to extend the healing ministry of Christ. For the latest news about AdventHealth, visit AdventHealth.com/news.
Tarin Patrikis
National Blood Clot Alliance
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and CB 2028 Allschwil, Switzerland – June 6, 2025Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period for the amended terms approved at the CB 2025 bondholder meeting of February 25, 2025 – during which no appeal was filed – it has published invitations to the next bondholder meetings for holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079). At the meetings, the company will propose changing the current terms of the CB 2025 and CB 2028 as part of the larger holistic restructuring, as announced in a press release on February 26, 2025, and an update published on May 21, 2025. To date, approximately 87% of the holders of the CB 2025 and 90% of holders of the CB 2028 have entered a legally binding lockup agreement in support of the holistic restructuring. Such bondholders have committed to vote in favour of the proposed amendments to the terms of the CB 2025 and CB 2028 at or before the meeting. The amendment of the terms of the CB 2025 and CB 2028 will be conditional on the consummation of the exchange offer, which is expected to be launched around or following the date of the bondholder meetings. Bondholders can access the invitations to the two bondholder meetings scheduled for Wednesday, June 25, 2025, including the terms of the resolution and additional information about the meeting, as well as a financial status report as of April 30, 2025, at the following links: and Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF
Yahoo
13 hours ago
- Yahoo
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn., June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock at a public offering price of $5.75 per share, which includes 2,610,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions. The total proceeds of the public offering were approximately $115.1 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering were sold by Trevi. Morgan Stanley, Leerink Partners, Stifel and Cantor acted as joint book-running managers for the offering. The shares were offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-273030), which was filed with the Securities and Exchange Commission (SEC) on June 29, 2023, amended on August 11, 2023 and declared effective by the SEC on August 15, 2023. This offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. The final terms of the offering are disclosed in a final prospectus supplement which has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@ or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York 10022, or by email at prospectus@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Investor Contact Jonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media Contact Rosalia Scampoli914-815-1465 rscampoli@ View original content to download multimedia: SOURCE Trevi Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
13 hours ago
- Indianapolis Star
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
NEW YORK CITY, NEW YORK / ACCESS Newswire New to The Street, the nation's leading multi-platform financial news show, today announced it has signed a 12-part media partnership with NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company focused on life-saving therapies for patients with suicidal depression, PTSD, and chronic pain. The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District. 'Our mission has always been to save lives with science,' said Jonathan Javitt, MD, MPH, Founder and CEO of NRx Pharmaceuticals. 'Partnering with New to The Street enables us to share the life-saving potential of NRX-101 and our broader pipeline with a national audience, at a pivotal moment in our regulatory and commercial path.' 'We are proud to bring NRX's critical work to our global audience,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'This series will spotlight a company on the front lines of neuroscience and public health, and exemplifies our commitment to covering stories that matter-with scale, credibility, and impact.' The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street's YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and platforms. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at About New to The Street New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at SOURCE: New To The Street View the original press release on ACCESS Newswire
